Starpharma and Telix are both companies involved in radiopharmaceuticals, and they have collaborated on projects and presented at conferences together:
Starpharma
A company that presented at the Radiopharmaceuticals Summit, where speakers from Telix and other companies shared insights on research and development. Starpharma also announced data on its DEP HER2-zirconium imaging product for breast cancers.
Telix
A biopharmaceutical company that develops and commercializes radiopharmaceuticals for diagnosis and treatment. Telix has collaborated with Starpharma on projects, including the Illuccix radiodiagnostic for prostate cancer, which was approved by the FDA and Therapeutic Goods Administration in 2021. Telix also participated in a panel discussion with Starpharma and Clarity Pharmaceuticals at the Wilsons Conference.
TLX Price at posting:
$24.44 Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)